Ixazomib - the first oral proteasome inhibitor

Related Experiment Video

Updated: Jan 31, 2026

Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.1K

Jingmei Xie1, Ning Wan2,3, Zhuoru Liang1

  • 1a College of Pharmacy , Jinan University , Guangzhou , PR China.

Leukemia & Lymphoma
|January 8, 2019
PubMed

Insights

Ixazomib is an oral proteasome inhibitor that significantly prolongs progression-free survival in relapsed/refractory multiple myeloma (RRMM). This first-in-class oral therapy offers a manageable safety profile for patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ixazomib is a proteasome inhibitor targeting the β5 subunit of the 20S proteasome.
  • Relapsed/refractory multiple myeloma (RRMM) presents a significant unmet need for effective oral therapies.

Purpose of the Study:

  • To review the clinical pharmacology, efficacy, tolerability, safety, and cost-effectiveness of ixazomib.
  • To summarize the findings of the TOURMALINE-MM1 study regarding ixazomib in RRMM.

Main Methods:

  • Review of clinical trial data, focusing on the TOURMALINE-MM1 study.
  • Analysis of pharmacological properties, efficacy endpoints, adverse events, and cost-effectiveness.

Main Results:

  • Ixazomib, combined with lenalidomide and dexamethasone, demonstrated prolonged progression-free survival (20.6 vs. 14.7 months) compared to placebo in RRMM patients.
  • The drug exhibited a favorable and manageable safety profile with primarily low-grade hematological, digestive, and cutaneous events.
  • Ixazomib is the first oral proteasome inhibitor approved for RRMM, offering a convenient treatment option.

Conclusions:

  • Ixazomib represents a significant advancement in the oral treatment of relapsed/refractory multiple myeloma.
  • Its efficacy, favorable safety profile, and oral administration support its role in managing RRMM.
  • Ongoing research aims to further define ixazomib's utility in various treatment settings, including first-line, maintenance, and relapse therapies.
Keywords:
Ixazomibproteasome inhibitorrelapsed/refractory multiple myeloma

More Related Videos

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach09:57

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Published on: December 17, 2016

7.0K
Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux09:18

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

5.0K

Related Concept Videos

The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.2K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
The Proteasome02:18

The Proteasome

4.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
575
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
1.7K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K